How to buy Genocea Biosciences stock | $2.36

Genocea Biosciences, Inc is a biotechnology business based in the US. Genocea Biosciences shares (GNCA) are listed on the NASDAQ and all prices are listed in US Dollars. Genocea Biosciences employs 72 staff and has a trailing 12-month revenue of around 0.00.

Genocea Biosciences stock price (NASDAQ: GNCA)

Use our graph to track the performance of GNCA stocks over time.

Genocea Biosciences shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$2.36
52-week range	$1.80 - $5.75
50-day moving average	$2.28
200-day moving average	$2.62
Wall St. target price	$6.68
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.38

Buy Genocea Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Genocea Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Genocea Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Genocea Biosciences price performance over time

Historical closes compared with the close of $2.36 from 2021-05-28

1 week (2021-07-18)	N/A
1 month (2021-06-29)	3.06%
3 months (2021-04-29)	-11.28%
6 months (2021-01-25)	N/A

1 year (2020-07-25)	N/A
2 years (2019-07-25)	N/A
3 years (2018-07-25)	N/A
5 years (2016-07-25)	N/A

Genocea Biosciences financials

Revenue TTM	$1.4 million
Gross profit TTM	$1.4 million
Return on assets TTM	-44.56%
Return on equity TTM	-579.95%
Profit margin	0%
Book value	$0.03
Market capitalisation	$112.7 million

TTM: trailing 12 months

Shorting Genocea Biosciences shares

There are currently 1.5 million Genocea Biosciences shares held short by investors – that's known as Genocea Biosciences's "short interest". This figure is 2.1% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Genocea Biosciences shares can be evaluated.

Genocea Biosciences's "short interest ratio" (SIR)

Genocea Biosciences's "short interest ratio" (SIR) is the quantity of Genocea Biosciences shares currently shorted divided by the average quantity of Genocea Biosciences shares traded daily (recently around 303083.96039604). Genocea Biosciences's SIR currently stands at 5.05. In other words for every 100,000 Genocea Biosciences shares traded daily on the market, roughly 5050 shares are currently held short.

However Genocea Biosciences's short interest can also be evaluated against the total number of Genocea Biosciences shares, or, against the total number of tradable Genocea Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genocea Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Genocea Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0559% of the tradable shares (for every 100,000 tradable Genocea Biosciences shares, roughly 56 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Genocea Biosciences.

Find out more about how you can short Genocea Biosciences stock.

Genocea Biosciences share dividends

We're not expecting Genocea Biosciences to pay a dividend over the next 12 months.

Have Genocea Biosciences's shares ever split?

Genocea Biosciences's shares were split on a 1:8 basis on 21 May 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genocea Biosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Genocea Biosciences shares which in turn could have impacted Genocea Biosciences's share price.

Genocea Biosciences share price volatility

Over the last 12 months, Genocea Biosciences's shares have ranged in value from as little as $1.8 up to $5.75. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genocea Biosciences's is 1.624. This would suggest that Genocea Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Genocea Biosciences overview

Genocea Biosciences, Inc. , a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. .

Frequently asked questions

What percentage of Genocea Biosciences is owned by insiders or institutions?
Currently 8.864% of Genocea Biosciences shares are held by insiders and 59.155% by institutions. How many people work for Genocea Biosciences?
Latest data suggests 72 work at Genocea Biosciences. When does the fiscal year end for Genocea Biosciences?
Genocea Biosciences's fiscal year ends in December. Where is Genocea Biosciences based?
Genocea Biosciences's address is: 100 Acorn Park Drive, Cambridge, MA, United States, 02140 What is Genocea Biosciences's ISIN number?
Genocea Biosciences's international securities identification number is: US3724274010 What is Genocea Biosciences's CUSIP number?
Genocea Biosciences's Committee on Uniform Securities Identification Procedures number is: 372427104